Tafalgie Therapeutics, a CNRS spin-off,
is a clinical-stage biotechnology company specializing in the development of next-generation painkillers
The company is pioneering the development of a new therapeutic class of non-opioid drugs capable of relieving and preventing acute and chronic pain without the adverse effects of current painkillers.
The treatments developed by the company are true breakthrough innovations stemming from the discovery of the analgesic effects of TAFA4, an endogenous protein secreted by humans that modulates the intensity of pain signals travelling between the peripheral and central nervous systems.
Their mode of action, fundamentally different from that of current painkillers, is disease-modifying, targeting the mechanisms underlying pain rather than simply relieving pain symptoms.
Aziz Mqrich
(Cofounder and CSO)
« During your life, there are moments that can change the course of your whole existence. Several years after my return from the United States — at a time at which the opioid crisis was just starting to emerge —I discovered the power of the endogenous protein TAFA4 to modulate pain and rapidly realized that I might have found a solution to a worldwide public health issue, something that could relieve patients’ pain without exposing them to the devastating adverse effects of current treatments.
This brought me face-to-face with new challenges that forced me to change dimension and create Tafalgie Therapeutics, a multicultural pluridisciplinary company run by passionate men and women ready to build a leading new actor in the domain of pain.»
Latest News
